AstraZeneca Pharma India Ltd saw its shares rise by 3% after announcing the launch of Breztri Aerosphere in January 2025. The company has received approval from the Drugs Controller General of India (DCGI) to import and market this inhalation therapy.
Breztri Aerosphere combines budesonide (160mcg), glycopyrronium (7.2mcg), and formoterol fumarate dihydrate (5mcg) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
The approval marks a significant step in AstraZeneca’s respiratory care portfolio, aligning with the growing demand for advanced COPD treatments in India.
As of 9:22 am, AstraZeneca Pharma shares were trading 2.01.% higher at Rs 6537.90 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.